- Market Realist•3 minutes ago
In 2017, Amgen’s (AMGN) leading oncology drug, Kyprolis, is expected to continue to be a dominant player in the second-line multiple myeloma space.
- Market Realist•2 hours ago
As cardiovascular diseases cost the global society around $600 billion annually, this segment is a huge growth opportunity for the pharmaceutical industry.
- Market Realist•3 hours ago
Wall Street analysts have projected that in 2017, Amgen’s revenues will reach ~$23.4 billion, which would mean a YoY (year-over-year) rise of ~2.7%.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||151.01 x 100|
|Ask||153.95 x 100|
|Day's Range||150.38 - 153.00|
|52 Week Range||133.64 - 176.85|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.20|
|Dividend & Yield||4.60 (2.97%)|
|1y Target Est||N/A|